📊 DSGN Key Takeaways
Is Design Therapeutics, Inc. (DSGN) a Good Investment?
Design Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and no clear path to profitability. The company is burning through cash at an annual rate exceeding $54M with only $16.9M in cash reserves, presenting a critical runway issue that threatens operational continuity within the next fiscal period.
Design Therapeutics remains a pre-revenue biotechnology company with no commercial revenue, deeply negative operating income, and substantial ongoing cash burn, so current fundamentals do not show a self-sustaining business model. The balance sheet is relatively clean with high reported liquidity, minimal liabilities, and no long-term debt, but profitability trends and free cash flow remain weak and make the company highly dependent on external funding or future pipeline execution.
Why Buy Design Therapeutics, Inc. Stock? DSGN Key Strengths
- Strong balance sheet with minimal debt (0.00x Debt/Equity) and $212.5M stockholders' equity
- Excellent liquidity position with 17.14x current ratio providing near-term operational flexibility
- Substantial asset base of $226.2M indicating accumulated capital investments in R&D
- Strong balance sheet with $212.50M of equity and only $13.70M of liabilities
- Very high current and quick ratios indicate near-term liquidity is currently strong
- No long-term debt reduces financial leverage risk and interest burden
DSGN Stock Risks: Design Therapeutics, Inc. Investment Risks
- Zero revenue generation with no commercial products, typical for early-stage biotech but creates existential cash burn risk
- Negative operating cash flow of -$54.4M annually with only $16.9M cash reserves implies critical funding runway of less than 4 months at current burn rate
- Negative ROE of -32.8% and ROA of -30.9% demonstrate value destruction with no near-term path to profitability based on available data
- No revenue base means operating losses are not being offset by commercial execution
- Negative operating cash flow and free cash flow indicate continued cash burn
- Returns on equity and assets are sharply negative, showing weak capital efficiency
Key Metrics to Watch
- Cash runway and timing of next financing requirement
- Clinical trial progress and regulatory milestones for pipeline assets
- Quarterly operating cash burn trends and management of operating expenses
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of revenue or major reduction in operating loss
Design Therapeutics, Inc. (DSGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.14x current ratio provides a solid financial cushion.
DSGN Profit Margin, ROE & Profitability Analysis
DSGN vs Healthcare Sector: How Design Therapeutics, Inc. Compares
How Design Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Design Therapeutics, Inc. Stock Overvalued? DSGN Valuation Analysis 2026
Based on fundamental analysis, Design Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Design Therapeutics, Inc. Balance Sheet: DSGN Debt, Cash & Liquidity
DSGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Design Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.88 indicates the company is currently unprofitable.
DSGN Revenue Growth, EPS Growth & YoY Performance
DSGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$13.0M | $-0.23 |
| Q2 2025 | N/A | -$11.8M | $-0.21 |
| Q1 2025 | N/A | -$11.1M | $-0.20 |
| Q3 2021 | $20.0K | -$2.3M | N/A |
| Q2 2021 | $31.0K | -$1.4M | N/A |
| Q1 2021 | $142.0K | -$663.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Design Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
DSGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Design Therapeutics, Inc. (CIK: 0001807120)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DSGN
What is the AI rating for DSGN?
Design Therapeutics, Inc. (DSGN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DSGN's key strengths?
Claude: Strong balance sheet with minimal debt (0.00x Debt/Equity) and $212.5M stockholders' equity. Excellent liquidity position with 17.14x current ratio providing near-term operational flexibility. ChatGPT: Strong balance sheet with $212.50M of equity and only $13.70M of liabilities. Very high current and quick ratios indicate near-term liquidity is currently strong.
What are the risks of investing in DSGN?
Claude: Zero revenue generation with no commercial products, typical for early-stage biotech but creates existential cash burn risk. Negative operating cash flow of -$54.4M annually with only $16.9M cash reserves implies critical funding runway of less than 4 months at current burn rate. ChatGPT: No revenue base means operating losses are not being offset by commercial execution. Negative operating cash flow and free cash flow indicate continued cash burn.
What is DSGN's revenue and growth?
Design Therapeutics, Inc. reported revenue of $0.0.
Does DSGN pay dividends?
Design Therapeutics, Inc. does not currently pay dividends.
Where can I find DSGN SEC filings?
Official SEC filings for Design Therapeutics, Inc. (CIK: 0001807120) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DSGN's EPS?
Design Therapeutics, Inc. has a diluted EPS of $-1.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DSGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Design Therapeutics, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DSGN stock overvalued or undervalued?
Valuation metrics for DSGN: ROE of -32.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DSGN stock in 2026?
Our dual AI analysis gives Design Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DSGN's free cash flow?
Design Therapeutics, Inc.'s operating cash flow is $-54.4M, with capital expenditures of $193.0K.
How does DSGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -32.8% (avg: 15%), current ratio 17.14 (avg: 2).